PT3101131T - Anticorpo antitranstirretina humanizado - Google Patents

Anticorpo antitranstirretina humanizado

Info

Publication number
PT3101131T
PT3101131T PT157432303T PT15743230T PT3101131T PT 3101131 T PT3101131 T PT 3101131T PT 157432303 T PT157432303 T PT 157432303T PT 15743230 T PT15743230 T PT 15743230T PT 3101131 T PT3101131 T PT 3101131T
Authority
PT
Portugal
Prior art keywords
transthyretin
humanized antibody
humanized
antibody
transthyretin humanized
Prior art date
Application number
PT157432303T
Other languages
English (en)
Original Assignee
Univ Kumamoto Nat Univ Corp
Km Biologics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kumamoto Nat Univ Corp, Km Biologics Co Ltd filed Critical Univ Kumamoto Nat Univ Corp
Publication of PT3101131T publication Critical patent/PT3101131T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0007Nervous system antigens; Prions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7047Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
PT157432303T 2014-01-29 2015-01-23 Anticorpo antitranstirretina humanizado PT3101131T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014014911 2014-01-29

Publications (1)

Publication Number Publication Date
PT3101131T true PT3101131T (pt) 2020-11-05

Family

ID=53756905

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157432303T PT3101131T (pt) 2014-01-29 2015-01-23 Anticorpo antitranstirretina humanizado

Country Status (7)

Country Link
US (1) US10604562B2 (pt)
EP (1) EP3101131B1 (pt)
JP (1) JP6818268B2 (pt)
KR (1) KR102538555B1 (pt)
CN (1) CN106574258B (pt)
PT (1) PT3101131T (pt)
WO (1) WO2015115331A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111471106A (zh) 2013-12-20 2020-07-31 生物控股有限公司 人源抗转甲状腺素蛋白抗体、多核苷酸、载体及其应用
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
JP6858868B2 (ja) * 2017-08-23 2021-04-14 富士フイルム株式会社 金属箔、金属箔の製造方法、二次電池用負極および二次電池用正極
BR112020003609A2 (pt) 2017-09-29 2020-09-01 Regeneron Pharmaceuticals, Inc. sistema e método para formar uma emulsão
CU20200022A7 (es) * 2017-10-06 2021-01-12 Prothena Biosciences Ltd Métodos para detectar transtiretina
EP3691447A4 (en) 2017-10-06 2021-08-11 Prothena Biosciences Limited ANTI-TRANSTHYRETINE ANTIBODIES
AU2018375356A1 (en) 2017-11-29 2020-05-14 Neotope Neuroscience Limited Lyophilized formulation of a monoclonal antibody against transthyretin
CN112888455A (zh) 2018-10-25 2021-06-01 Km生物医薬股份公司 修饰CMVgB蛋白及包含其的CMV疫苗
JP2022534867A (ja) 2019-06-04 2022-08-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ベータスリップ変異を有するヒト化ttr遺伝子座を含む非ヒト動物と使用方法
CN115551886A (zh) 2020-05-12 2022-12-30 生物控股有限公司 用于ttr淀粉样变性的联合疗法
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
WO2024121156A1 (en) 2022-12-05 2024-06-13 Neurimmune Ag Cyclic compounds and their use in assays for detecting antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1551918B (zh) 2001-07-06 2011-04-20 财团法人化学及血清疗法研究所 基因重组伊卡因及其制备方法
US20040151721A1 (en) * 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
KR101557173B1 (ko) 2007-10-25 2015-10-05 더 스크립스 리서치 인스티튜트 박테리아에서의 쿼럼 센싱의 항체 매개성 파괴
US8791243B2 (en) 2007-12-28 2014-07-29 Onclave Therapeutics Limited Treatment and prophylaxis of amyloidosis
WO2010030203A1 (en) 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
JP2010195710A (ja) * 2009-02-25 2010-09-09 Kumamoto Univ アミロイド線維形成抑制剤及びその利用
PE20150091A1 (es) * 2012-02-24 2015-02-16 Stem Centrx Inc Anticuerpos anti-sez6 y metodos de empleo
US9534048B2 (en) 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
WO2014124334A2 (en) * 2013-02-08 2014-08-14 Misfolding Diagnostics, Inc. Transthyretin antibodies and uses thereof

Also Published As

Publication number Publication date
JP6818268B2 (ja) 2021-01-20
JPWO2015115331A1 (ja) 2017-03-23
KR102538555B1 (ko) 2023-05-30
CN106574258B (zh) 2021-03-30
US20160347832A1 (en) 2016-12-01
WO2015115331A1 (ja) 2015-08-06
US10604562B2 (en) 2020-03-31
CN106574258A (zh) 2017-04-19
EP3101131B1 (en) 2020-08-19
EP3101131A1 (en) 2016-12-07
EP3101131A4 (en) 2017-06-28
KR20160113206A (ko) 2016-09-28

Similar Documents

Publication Publication Date Title
ZA201803874B (en) Humanized anti-cd73 antibodies
IL252004A0 (en) Ether-substituted antibody
IL250415A0 (en) Antibodies against pd-l1
HK1258375A1 (zh) 人源化抗-cll-1抗體
IL256579A (en) Human antibodies
IL248402A0 (en) Humanized antibodies against ceacam1
PT3101131T (pt) Anticorpo antitranstirretina humanizado
IL291164A (en) Anti-nme antibody
IL246603A0 (en) A new antibody against netrin-1
GB201410520D0 (en) Antibody
IL247371B (en) Antibodies from individuals with increased stability
SG11201700922YA (en) Anti-orai1 antibody
LT3628731T (lt) Naujas antipresepsino antikūnas
PL3371216T3 (pl) Humanizowane przeciwciała anty-BAG3
GB201418781D0 (en) Antibody epitope
GB201418776D0 (en) Antibody
GB201413745D0 (en) Antibody
GB201411319D0 (en) Antibody
GB201407535D0 (en) Antibody Drug - Conjugates